A phase I/II Octopus study, Quilt-3.055 (NCT03228667), recruited patients with diverse cancer types and focused on combining T cell modulation and PD-L1 inhibition for advanced cancer patients previously treated with immunotherapy [17]. Here, CD274 is linked to cancer.